GlassScriptPhysician profile
Uzma Abbasi
NPI 1275856106
$4,293.31
in general payments reported to CMS, 2019-2025
23 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $1,289 · 2021: $1,007 · 2022: $560 · 2023: $451 · 2024: $222 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.90 | 2019-2024 | Rinvoq, Skyrizi, Mavyret |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $706.09 | 2019-2024 | Xifaxan |
| Pfizer INC. | $533.75 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $390.74 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $358.96 | 2019-2023 | Stelara |
| Boston Scientific Corporation | $257.38 | 2019-2023 | Orca, Exalt Model D |
| Gilead Sciences, INC. | $143.28 | 2019-2025 | |
| Celgene Corporation | $139.85 | 2022-2024 | Zeposia |
| Allergan, INC. | $83.60 | 2019-2020 | |
| Genzyme Corporation | $63.69 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $61.32 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $57.06 | 2020-2022 | |
| Lilly USA, LLC | $47.60 | 2024 | Omvoh |
| Redhill Biopharma INC. | $44.36 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $39.56 | 2025 | Vowst |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $35.64 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $31.33 | 2023 | Dupixent |
| Alfasigma USA, INC. | $30.67 | 2020 | |
| Novo Nordisk INC | $24.82 | 2025 | Wegovy |
| Ucb, INC. | $21.05 | 2019 | |
| Shire North American Group INC | $16.47 | 2019 | |
| Medtronic, INC. | $15.84 | 2025 | Pillcam |
| Intercept Pharmaceuticals, INC. | $15.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Abbasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.